Market Overview

UPDATE: Piper Jaffray Cuts PT to $15 on Achillion Pharmaceuticals on Equity Offering Dilution

Related ACHN
Barclays Expands Coverage To 7 New Biotech Stocks
After-Hours Movers Led By Bob Evans, Bazaarvoice And Smith & Wesson On Tuesday
Gilead's Hepatitis C Drug Sovaldi Gets Approval in Japan - Analyst Blog (Zacks)

Piper Jaffray maintained Achillion Pharmaceuticals (NASDAQ: ACHN) with an Overweight rating and lowered the price target from $16.00 to $15.00.

Piper Jaffray said, "Achillion now holds proforma cash of $211 million following a recent 16.9 million share offering. We are buyers of ACHN shares ahead of SVR-4 data from the 12-week trial of ACH-3102 + ribavarin in 8 HCV genotype 1b patients at EASL in April. … We continue to see Achillion as a likely take-out candidate for its promising HCV pipeline. We reiterate our Overweight rating, however are trimming our price target to $15 from $16 price target due to dilution from the equity offering."

Achillion Pharmaceuticals closed at $8.15 on Friday.

Latest Ratings for ACHN

Mar 2015BarclaysInitiates Coverage onUnderweight
Dec 2014BairdDowngradesOutperformNeutral
Dec 2014Deutsche BankMaintainsBuy

View More Analyst Ratings for ACHN
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Analyst Ratings


Related Articles (ACHN)

Around the Web, We're Loving...